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ORIGINAL ARTICLE

A Retrospective Study on the Predictors of Outcome
in Patients with Infective Endocarditis
Yuen-Fung Yiu
Department of Medicine and Geriatrics, Princess Margaret Hospital, Hong Kong

Abstract
Background: Infective endocarditis (IE) is associated with signiﬁcant mortality and morbidity. This study aims to update the epidemiology of IE and to identify predictors of adverse outcome in the Chinese population in Hong Kong.
Methods: This was a single-centre retrospective study of patients diagnosed with IE in Princess Margaret Hospital in
Hong Kong during 2002e2016. Primary outcome was deﬁned as in-hospital mortality. Secondary outcomes included 1year mortality, valvular surgical intervention, heart failure, stroke and systemic embolization.
Results: In total, 196 patients with deﬁnite or possible IE were included in the study. The incidence of IE was 2.26 per
100,000 person-years and had remained stable. Health care-associated IE (HCAIE) accounted for 32% of cases, with an
increasing trend. Staphylococcus aureus was the most frequently isolated organism in the overall study population
(37.8%) and among intravenous drug users (85.2%). In-hospital mortality remained high (29.1%) and was independently
associated with higher Charlson Comorbidity Index (OR 1.24, p ¼ 0.001), heart failure (OR 5.65, p < 0.001) and the
presence of large vegetation ≥ 1 cm (OR 4.67, p < 0.001). IE due to Streptococcus viridans was associated with a better
outcome (OR 0.40, p ¼ 0.048).
Discussion: This study showed that the incidence of IE remained stable during 2002e2016. There was an increasing
proportion of HCAIE and S. aureus has become the most common causative organism. IE was associated with high
mortality and morbidity. Independent predictors for in-hospital mortality were patient's medical comorbidity, large
vegetation size and heart failure, while infection by viridans group streptococci was associated with reduced risk.
Keywords: Endocarditis, Bacterial, Heart valve diseases, Incidence, Treatment outcome

Introduction

I

nfective endocarditis (IE) is deﬁned as an infection involving the endocardial surface of the
heart or great vessels. The heart valves, both native
and prosthetic, are the most commonly affected and
other cardiac structures including the chordae tendineae, sites of septal defects and the mural endocardium can also be involved [1]. The majority of
contemporary epidemiological studies on IE were
performed in the Western countries. It has been
shown that the epidemiology and microbiology of IE
has signiﬁcantly changed in the recent decade.

However, local data is sparse and the most recent
study on IE in our population was already performed more than ten years ago [2]. This study aims
to provide an update on the epidemiology and to
identify predictors of adverse outcome of IE in the
Chinese population in Hong Kong.

Methods
This single-center retrospective study was conducted at Princess Margaret Hospital, a major acute
hospital providing service for patients in the Kowloon West Cluster. All medical records of patients
diagnosed with IE from the years 2002e2016 were
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identiﬁed in the Clinical Data Analysis and
Reporting System (CDARS) according to the International Classiﬁcation of Disease codes. The diagnosis of IE was deﬁned by the Modiﬁed Duke's
Criteria and patients were further classiﬁed into
‘deﬁnite’ and ‘possible’ IE accordingly. All patients
aged 18 years or older, who were Hong Kong permanent residents, with deﬁnite or possible IE were
enrolled in the study. Patients who were subsequently given a ﬁrm alternate diagnosis or those
with incomplete clinical information were excluded.
Demographic data, clinical manifestation, laboratory and microbiological ﬁndings, imaging characteristics, treatment and in-hospital outcome
information were retrieved from the electronic patient record system.
IE episodes were classiﬁed based on the valvular
involvement and whether native (NVE) or prosthetic valve (PVE) was involved. Cases were also
classiﬁed into health care-associated IE (HCAIE)
and community-acquired IE [3]. HCAIE was further
classiﬁed into nosocomial and non-nosocomial.
Nosocomial IE was deﬁned as IE in a patient who
had been hospitalized for >48 hours before the
onset of signs or symptoms consistent with IE. Nonnosocomial HCAIE was deﬁned as IE diagnosed
within 48 hours of admission with any of the
following criteria: (1) receipt intravenous therapy,
wound care, or specialized nursing care at home
within the 30 days before the onset of IE; (2) attendance at a hospital or hemodialysis clinic or receipt
of intravenous chemotherapy within the 30 days
before the onset of IE; (3) hospitalization in an acute
care hospital for 2 days during the 90 days before
the onset of IE; or (4) residence in a nursing home or
long-term care facility. Community-acquired IE was
deﬁned as IE diagnosed within the ﬁrst 48 hours of
admission in a patient who did not fulﬁll the criteria
for health care-associated infection. Pre-existing
comorbidities were evaluated using the Charlson
Comorbidity Index (CCI).
Echocardiography (both transthoracic and transesophageal) images and reports were reviewed. The
location and size of vegetation, presence and severity
of valvular insufﬁciency and peri-valvular involvement were recorded. Vegetations were deﬁned as
large if the largest diameter exceeded 1 cm [4]. Perivalvular abscess was deﬁned as a circular or more
irregularly delineated region (>10 mm) of reduced
echo density, without ﬂow in its interior.
Patients were followed up for 1 year since diagnosis. Primary outcome was deﬁned as in-hospital
mortality. Secondary endpoints included 1-year
mortality, valvular surgical intervention, heart failure, stroke and systemic embolization (SE). Events
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due to obvious atherosclerosis or cardiogenic embolism unrelated to IE and cutaneous manifestation
of IE were excluded. Surgery (valvular replacement
and/or valve repair) was deﬁned as early, if the
operation was performed during the initial hospitalization before the completion of full course of
antibiotics [5].
Statistical analysis
Continuous variables were expressed as
mean ± standard deviation (SD) for normal distribution and median ± interquartile range (IQR) for
non-normal distribution. Categorical variables were
presented as frequencies and percentages. Statistical comparisons were performed using Student's t
test or Chi-square test, as appropriate.
To estimate the incidence of IE, the adult population of the Kowloon West Cluster served by our
hospital would be considered to be at risk. The
overall incidence rate during the 15-year study
period and individual incidence rate in each year
were calculated.
The primary outcome for this study was all-cause
mortality during the index hospitalization. Logistic
regression analysis was performed to determine
parameters associated with in-hospital death.
Further analyses were performed with a backward
stepwise multivariable logistic regression analysis
that included clinical, microbiological and echocardiographic variables with P < 0.1 according to univariate analysis. All statistical analyses were
performed using IBM SPSS Statistics for Windows
(version 25.0. Armonk, NY: IBM Corp). A p value of
<0.05 would be considered statistically signiﬁcant.

Results
Between January 2002 and December 2016, 315
potential subjects were identiﬁed from the CDARS.
66 cases were excluded as they failed to fulﬁl the
modiﬁed Duke's criteria. 35 cases were excluded
since a ﬁrm alternative diagnosis was present. 18
cases were excluded because of incomplete data. A
total of 196 patients were included in the study. The
overall incidence (event per 100,000 person-years) of
IE was 2.26, it was the lowest in 2003 (1.21) and was
the highest in 2004 (3.23). No signiﬁcant temporal
trend was identiﬁed (p for trend ¼ 0.38).
Demographic characteristics and predisposing
conditions
The demographic characteristics of the study
population is presented in the Table 1. One hundred
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Table 1. Patient demographics and predisposing conditions in 196 patients with IE.
Characteristic

No. (%) / Median (IQR)

Age
Male gender
Charlson Comorbidity Index
Chronic liver disease
Diabetes
Chronic renal impairment
Hemodialysis
Peritoneal dialysis
Heart failure
Intravenous drug use
Recent invasive procedures
Malignancy
COPD
Deﬁnite IE
Predisposing conditions
Rheumatic heart disease
Mitral valve prolapse
Prosthetic valve
Congenital heart disease
History of IE

60.2 (45.4e72.1)
132 (67.3)
3 (1e5)
41 (20.9)
38 (19.4)
37 (18.9)
10 (5.1)
7 (3.6)
35 (17.9)
27 (13.8)
20 (10.2)
19 (9.7)
8 (4.1)
166 (84.7)
27
28
19
16
16

(13.8)
(14.3)
(9.7)
(8.2)
(8.2)

COPD, chronic obstructive pulmonary disease; IE, infective
endocarditis.

and sixty-six patients (84.7%) were classiﬁed as
deﬁnite IE. The median (IQR) age was 60.2
(45.4e72.1) and 100 patients (51%) were above 60
years old. One hundred and thirty-two patients
(67.3%) were male and the male/female ratio was
2.1. Underlying medical comorbidities were common. Diabetes mellitus was present in 19.4% of the
patients, 18.9% of the patients had chronic renal
impairment and 3.6% were on hemodialysis.
Twenty-seven patients (13.8%) had a history of
intravenous drug use. Mitral valve prolapse and
chronic rheumatic heart disease were the two
commonest predisposing conditions, present in 28
patients (14.3%) and 27 patients (13.8%) respectively.
Nineteen patients (9.7%) had a prosthetic heart
valve. A history of previous IE and congenital heart
disease were both present in 16 patients (8.2%). An
invasive procedure done within 60 days was documented in 20 patients (10.2%).
Clinical and echocardiographic ﬁndings
According to the mode of acquisition, 133 IE episodes (67.9%) were classiﬁed as community-acquired, 23 episodes (11.7%) as nosocomial and 40
episodes (20.4%) as non-nosocomial HCAIE.
The clinical manifestations of the patients are
shown in Table 2. Fever was the most common
presenting symptom and was present in 93.4% of
patients. A new onset or a worsening cardiac
murmur was reported in 38.8% of patients. Hematuria was noted in 17 (8.7%) patients while

Table 2. Clinical features of the patients with infective endocarditis.
Clinical feature

No. (%) /
Median (IQR)

Fever
New murmur
Hematuria
Osler nodes
Janeway lesions
Splenomegaly
Splinter hemorrhage
Vascular embolic event
Roth spots
Time from symptom onset to admission (days)
Time from symptom onset to diagnosis (days)
Complications
Heart failure
Non-stroke embolization
Stroke
New onset atrial ﬁbrillation
Intracardiac abscess
Atrioventricular block

183 (93.4)
76 (38.8)
17 (8.7)
8 (4.1)
6 (3.1)
6 (3.1)
4 (2.0)
4 (2.0)
3 (1.5)
3 (1e11)
10 (6e17)
85 (43.4)
38 (19.4)
37 (18.9)
12 (6.1)
7 (3.6)
3 (1.5)

glomerulonephritis was seen in 8 patients (4.1%).
Other classical signs of IE including splinter hemorrhage, Osler's nodes, Janeway lesions and Roth's
spots were uncommon, each present in less than 5%
of the study population. Most patients presented
early and the median number of days from symptom onset to admission was 3 (1e11).
Anemia was a common ﬁnding on admission,
present in 76.3% of patient. Although up to 26.9% of
patient had a normal white cell count, 99.4% of patients with IE had an elevated C-reactive protein
levels. Acute renal failure was observed in 6 patients
(4.0%) without history of chronic kidney disease.
Transthoracic echocardiography was performed
in 195 (99.4%) patients and 38.5% of patients had
both
transthoracic
and
transesophageal
Table 3. Echocardiographic ﬁndings in patients with infective
endocarditis.
Characteristic
Valve involved
Aortic
Mitral
Aortic þ mitral
Tricuspid
Pulmonary
Valve type
Native
Prosthetic
Echocardiographic diagnosisa
Transthoracic
Transesophageal
Valvular damage
Vegetation
Size  1 cm
Moderate/severe regurgitation
Peri-valvular abscess
a

One case was diagnosed by autopsy.

Number (%)
29 (14.8)
104 (53.1)
8 (4.1)
27 (13.8)
4 (2.0)
177 (90.3)
19 (9.7)
120 (61.5)
75 (38.5)
172 (87.8)
96 (49.0)
91 (46.4)
7 (3.6)

7

J HK COLL CARDIOL 2022;29(1):4e12

echocardiography (Table 3). One patient died before
echocardiography could be arranged and the diagnosis of IE was established at autopsy. Vegetation
was found in 172 patients (87.8%), of which 96 patients (49%) had a large vegetation with maximum
diameter 1 cm. The left-sided heart valves were
involved in the majority of cases (82.0%) and the
mitral valve was the most commonly affected
(65.1%). 91 patients (46.4%) had moderate or severe
valvular regurgitation as a result of valvular damage. Peri-valvular abscess was observed in 7 patients (3.6%).

associated with MSSA as causative organism (OR
4.63, p ¼ 0.03). Viridans streptococci was the second
commonest organism in the overall population and
the commonest among non-intravenous drug users.
Streptococcus bovis was the next commonest streptococcus and was found in 12 patients (6.1%). Its
classic association with colorectal pathology was
conﬁrmed in this population. Eight of the 10 patients
who subsequently underwent a colonoscopy were
diagnosed to have colorectal adenoma or cancer.

Microbiology

One hundred and ninety-ﬁve patients (99.4%)
were treated with antimicrobial therapy. One patient deteriorated rapidly after admission and
passed away before antibiotic could be administered. The majority of patients received empirical
treatment within 24 hours after admission, with the
combination of amoxicillin and clavulanic acid as
the commonest drug of choice (64.5%). Overall, the
median time between hospital admission and
administration of appropriate deﬁnitive antibiotics
was 5 days (IQR 5e7). Emergency or urgent surgery
was performed in 17 patients (8.6%) but 11 of them
(64.7%) died despite surgery. In 7 patients, valvular
surgery was planned but impeded because the patient deteriorated or was deceased before operation.
Among the patients who survived till hospital
discharge, treatment duration was less than 4 weeks

The distribution of causative pathogens in the
study period was shown in Table 4. Staphylococcus
aureus was the most frequently isolated organism in
the overall study population (37.8%) and among
intravenous drug users (85.2%). Methicillin-sensitive S. aureus (MSSA) remained much more common than methicillin-resistant S. aureus (MRSA).
During 2002e2011, only 2% of S. aureus isolated was
methicillin-resistant but the proportion grew to 20%
in 2012e2016, with a signiﬁcant trend (p ¼ 0.011).
The microbiological etiology varies according to
the location of acquisition. HCAIE were associated
with S. aureus infection whereas the majority of
community-acquired IE was associated with S. viridans. Patients on chronic hemodialysis was also

Treatment

Table 4. Etiology microorganism of infective endocarditis.
Microorganism
Staphylococci
Methicillin-sensitive Staphylococcus aureus
Methicillin-resistant Staphylococcus aureus
Coagulase negative staphylococci
Streptococcaceae
Viridians streptococci
Streptococcus bovis
Group G Streptococci
Streptococcus agalactiae
Gemella morbillorum
Granulicatella adiacens
Streptococcus constellatus
Streptococcus intermedius
Enterococci
HACEKa
Fungus
Candida albicans
Candida glabrata
Others
Gram-negative rodsb
Abiotrophia defectiva
Corynebacterium striatum
Lactococcus garvieae
Negative culture
a
b

Total (n ¼ 196)

Non-IVDU (n ¼ 169)

IVDU (n ¼ 27)

67 (34.2)
7 (3.6)
11 (5.6)

44 (26.0)
7 (4.1)
11 (6.5)

23 (85.2)
e
e

55 (28.1)
12 (6.1)
6 (3.1)
5 (2.6)
1 (0.5)
1 (0.5)
1 (0.5)
1 (0.5)
7 (3.6)
2 (1.0)

54 (32.0)
12 (7.1)
6 (3.6)
5 (3.0)
1 (0.6)
1 (0.6)
1 (0.6)
1 (0.6)
7 (4.1)
2 (1.2)

1 (3.7)
e
e
e
e
e
e
e
e
e

1 (0.5)
1 (0.5)

1 (0.6)
1 (0.6)

e
e

5
3
2
1
7

5
3
1
1
5

e
e
1 (3.7)
e
2 (7.4)

(2.6)
(1.5)
(1.0)
(0.5)
(3.6)

(3.0)
(1.8)
(0.6)
(0.6)
(3.0)

Refers to Haemophilus species, Aggregatibacter species, Cardiobacterium hominis, Eikenella corrodens, and Kingella species.
Including two group D Salmonella, one Bacteroides fragilis, one Enterobacter cloaecae and one Klebsiella pneumonia.
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Table 5. Clinical outcomes and complications of patients with infective
endocarditis.
Outcome

Number (%)

Mortality
In-hospital
One-year
Valvular surgery
Early
Elective
Heart Failure
Stroke
Non-stroke embolization
Lungs
Skeletal system
Spleen
Limbs
Kidney
Coronary artery
Peri-valvular abscess
Relapse or recurrence

57 (29.1)
15 (7.7)
17 (8.6)
31 (15.8)
85 (43.4)
37 (18.9)
38 (19.4)
14 (7.1)
9 (4.6)
7 (3.6)
6 (3.1)
4 (2.0)
1 (0.5)
7 (3.6)
21/139 (15.1)

in 14.4 of cases, between 4 and 6 weeks in 54.7% and
longer than 6 weeks in 30.9%. Seventeen patients
(8.7%) patients were managed by out-patient
parenteral antibiotic therapy (OPAT). The duration
of hospital stay ranged from 1 to 167 days, with a
median of 39 (IQR 29e49) days. When the patients
who died during hospital stay were excluded, the
median length of stay was 42 (IQR 33e53) day.
OPAT was associated with a signiﬁcantly shorter
median length of stay (20 vs 43 days, p < 0.001).
Outcome
The clinical outcomes and complications of patients with IE were summarized in Table 5. Heart

failure was the commonest complication and
occurred in 43.4% of patients. 19.4% of patient suffered at least one episode of systemic embolization,
with lungs being the commonest site. Stroke was
reported in 18.9% of patients.
A total of 57 in-hospital deaths occurred (in-hospital mortality ¼ 29.1%). Patient with possible IE
had similar outcome as those with deﬁnite IE
(p ¼ 0.451).
Multivariable analysis revealed that Charlson
Comorbidity Index (OR 1.24, p ¼ 0.001), heart failure
(OR 5.65, p < 0.001) and the presence of large
vegetation (OR 4.67, p < 0.001) were independent
predictors for in-hospital mortality, while Streptococcus viridans IE was an independent favorable
predictor (OR 0.40, p ¼ 0.048) (Table 6). Health careassociated IE was associated with a higher mortality
than community acquired IE (52.4% vs 18.0%;
P < 0.001), but the association became insigniﬁcant
after adjustment for Charlson comorbidity index.
The crude survival rate at one-year follow-up was
89.2% but up to 10% of survivors suffered an
episode of relapse or recurrence at 1 year and 21%
required elective cardiac surgery after hospital
discharge.
Temporal trends
The overall incidence remained stable and did not
change signiﬁcantly over time (p > 0.05 for trends,
Table 7). The age and Charlson Comorbidity Index
of patients remained similar. The proportion of patients with intravenous drug usage or prosthetic

Table 6. Univariable and multivariable logistic regression for the predictors for in-hospital mortality in patients with infective endocarditis.
Characteristics

Univariable
ORunadj (95% CI)

p value

Age at admission (years)
Male
IVDU
Comorbidity index
Hemodialysis
Prosthetic valve
Underlying heart disease
Congenital heart disease
Rheumatic heart disease
Mitral valve prolapse
Deﬁnite IE
Health care-associated IE
Heart failure
Stroke
Non-stroke embolization
Vegetation
Vegetation size  1 cm
Microbiological
Positive culture
MSSA
S. viridans

1.02
0.96
0.51
1.22
3.97
0.86

(1.00e1.04)
(0.50e1.84)
(0.18e1.42)
(1.10e1.36)
(1.08e14.65)
(0.29e2.51)

0.035
0.897
0.199
<0.001
0.038
0.780

0.54
0.51
0.36
1.42
3.72
4.92
1.90
1.35
1.52
4.22

(0.15e1.97)
(0.18e1.43)
(0.12e1.09)
(0.57e3.51)
(1.73e7.98)
(2.52e9.60)
(0.90e4.00)
(0.63e2.87)
(0.53e4.31)
(1.98e9.00)

0.349
0.199
0.072
0.453
0.001
<0.001
0.091
0.439
0.433
<0.001

2.53 (0.30e21.47)
1.02 (0.53e1.95)
0.43 (0.20e0.92)

Multivariable

0.396
0.960
0.030

ORadj (95% CI)

p value

1.24 (1.09e1.41)

0.001

5.65 (2.63e12.14)

<0.001

4.67 (2.12e10.31)

<0.001

0.40 (0.16e0.99)

0.048

IVDU, intravenous drug use; IE, infective endocarditis; MSSA, methicillin sensitive Staphylococcus aureus.
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Table 7. Temporal trends in incidence and characteristics of infective endocarditis.
Year
02e06

Incidence per 100,000 persons
Age, years
Men, n (%)
Comorbidity index
IVDU
Non-nosocomial HCAIE
Prosthetic valves
Organisms
Staphylococcus aureus
Streptococcus viridans
Others
Stroke
Non-stroke embolic events
In-hospital mortality
Early surgery
LOS of survivors (days)

p value
07e11

12e16

(n ¼ 71)

(n ¼ 61)

(n ¼ 64)

2.78 (2.20e3.50)
56.3 ± 18.3
44 (62.0)
3.2 ± 2.5
10 (14.1)
11 (15.5)
6 (8.5)

1.96 (1.52e2.51)
58.1 ± 17.5
42 (68.9)
3.8 ± 3.2
9 (14.8)
10 (16.4)
8 (13.1)

2.04 (1.60e2.61)
59.9 ± 18.1
46 (71.9)
3.7 ± 3.1
8 (12.5)
19 (29.7)
5 (7.8)

26 (36.6)
20 (28.2)
21 (29.6)
16 (22.5)
14 (19.7)
22 (31.0)
4 (5.6)
46.2 ± 21.3

18 (29.5)
17 (27.9)
24 (39.3)
11 (18.0)
10 (16.4)
19 (31.1)
8 (13.1)
43.7 ± 16.8

30 (46.9)
18 (28.1)
15 (23.4)
10 (15.6)
14 (21.9)
16 (25.0)
5 (7.8)
47.4 ± 28.7

0.082
0.510
0.451
0.383
0.931
0.044
0.549
0.283

0.580
0.738
0.681
0.300
0.746

IVDU, intravenous drug use; HCAIE, health care-associated infective endocarditis; LOS, length of stay.

heart valves did not change signiﬁcantly with time.
However, there was a signiﬁcant trend of increasing
proportion of patients with health care-associated IE
(p ¼ 0.044). The distribution of causative organism
remained similar during the study period. No signiﬁcant trend was observed in patient outcomes
regarding in-hospital mortality, stroke, systemic
embolic events or surgery.

Discussion
Incidence
This study updates the epidemiology of infective
endocarditis in the Kowloon West Cluster of Hong
Kong over the past 15 years. While numerous
Western studies have demonstrated an increasing
incidence of IE in the recent decade, our study
showed that the local incidence was relatively low
and has remained stable over the past ﬁfteen years,
conﬁrming the ﬁndings of another local study performed in 1995e2005 [2]. It has been controversial
whether the change in guideline recommendations
on antibiotic prophylaxis had resulted in an increase
in incidence of IE. In accordance to previous studies
[6,7], our data did not show an increase in incidence
of overall IE or IE associated with viridans group
streptococci. Our study has a lower proportion of IE
related to intravenous drug use (IVDU) (13.8%), in
contrast to the 30% reported by an earlier local
study [2]. Although the number of reported drug
abusers in Hong Kong has been declining since 2008
[8], a decreasing trend of IVDU-related IE has not

yet been apparent. Health care-associated IE
accounted for 15.5% of all IE in 2002e2006 and
29.7% in 2011e2016, showing a signiﬁcant
increasing trend consistent with most of the recent
reports in developed countries [9].
Clinical features
The age and sex distribution of the study population were consistent with the recent studied performed in other high-income countries [10]. Fever
and new cardiac murmur were the two commonest
presenting clinical features. For the laboratory parameters, anemia to various degrees was present in
the majority of patients (76.3%). Up to 27% of patients had a normal white cell count on admission,
C-reactive protein was more sensitive and was
found elevated in the vast majority of patients
(99.4%).
Microbiology
In our series, 15% of patients were culture negative, this rate was comparable to that reported in
previous studies [2,3]. Our study has also observed
the shift in microbiology of IE seen in other parts of
the world with S. aureus overtaking streptococci as
the most common causative organism of IE. The
shift can be explained by the increase in prevalence
of risk factors associated with S. aureus infection, for
example health care contact and invasive procedures. As a whole, MRSA was relatively uncommon
in our study population as compared with other
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developed countries [10,11]. However, we have
observed a worrisome trend of increase in MRSA.
Six of the total 7 (85.7%) cases caused by MRSA
were diagnosed in recent years. During 2012e2016,
20% of the isolated S. aureus were found to be
methicillin-resistant. This is a cause of concern,
given the known association between MRSA and
adverse outcomes.
Echocardiographic ﬁndings
Echocardiography was performed in the vast
majority of the study population. The detection rate
of a vegetation was 87.8%, which was similar to
previous patient cohorts [3]. The distribution of
location of the vegetation was also similar to other
previous Asian studies [2,5], with mitral valve being
the most frequently affected. However, studies from
the West usually showed a predominance of aortic
valve involvement [10,12,13]. The reason for this
difference is unclear.
Large vegetations with size 1 cm have been seen
in 49% of patients, and was associated with higher
in-patient mortality and risk of urgent surgery.
However, the association between the size of vegetation and risk of systemic embolism did not reach
statistical signiﬁcance.
Treatment and outcome
Estimated mortality related to IE varies signiﬁcantly in different series and has been reported to
range from 15 to 30% [14e16]. The in-hospital
mortality of the study population was estimated at
29%. This ﬁgure was on the high side, but was
comparable to that of a recent Japanese study [5].
Despite the advances in technology in diagnosis and
treatment, no signiﬁcant improvement in patient
outcome in terms of in-hospital mortality has been
observed over the years.
The rate of systemic embolism, on the other hand,
was unexpectedly low compared to previous studies
[17]. This is more likely a reﬂection of low detection
rate in our study population. Studies have demonstrated that advanced imaging modalities like
whole-body computed tomography, cerebral magnetic resonance imaging, positron emission tomography or single photon emission computed
tomography could improve detection of silent
vascular phenomenon [18]. However, in usual hospital setting, these imaging modalities were uncommonly employed due to the limitation of
resource.
In the past, while some selected patients with IE
on chronic hemodialysis could be managed as out-

patient and receive the antibiotic during scheduled
hemodialysis, most patients with IE required at least
4e6 weeks of hospitalization for antibiotic treatment. Out-patient Parenteral Antibiotic Therapy
(OPAT) service was initiated in our hospital in 2013
and has allowed medically stable patients to complete the full course of antibiotic treatment in the
out-patient setting. Our data showed that OPAT
signiﬁcantly shortened the median length of stay (20
vs 43 days, p < 0.001).
Only 48 patients (24.5%) underwent cardiac surgery and 17 (8.6%) had surgery performed during
the in-hospital phase. This surgery rate was significantly lower than that reported by most other patient cohorts [5,12,13,15]. Possible explanations to
this difference are two-fold. First, on-site cardiothoracic surgical support was not available in our
hospital. This may delay the timing of consultation
with cardiac surgeons. In addition, a portion of patients who were initially planned for early operation
had deterioration of clinical status before interhospital transferal and were eventually rejected for
surgery. Second, our study has included patients
with advanced age or multiple comorbidities. This
group of patients were more likely to be turned
down by cardiac surgeons or prefer conservative,
non-operative treatment. Our data suggested
that patients who underwent early surgery were
generally healthier at baseline, with signiﬁcantly
fewer medical comorbidities (CCI 1.9 vs 3.7,
p ¼ 0.01).
Predictors of outcome
Several factors have been found to be independently associated with in-hospital mortality in this
study. While different cut-off levels have been used
to deﬁne a large vegetation, most studies demonstrated a consistent association between the size of
vegetation and worse clinical outcome [4,17]. Our
study showed that patients with a vegetation 1 cm
in length had 4- to 5-fold increase in in-hospital
mortality.
Heart failure has been consistently shown to
predict in-hospital and long term mortality [15].
This study has conﬁrmed this ﬁnding and showed
that development of clinical heart failure was the
strongest risk factor for in-hospital death (OR 5.65,
p < 0.001).
Age and hemodialysis were associated with mortality in univariable analysis. They were not entered
into the multivariable model because they have
been included in the Charlson Comorbidity Index.
Charlson Comorbidity Index was initially developed
for classifying comorbid conditions which may
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affect the risk of mortality in longitudinal studies. It
has taken into account a number of patient characteristics and comorbid diseases including age, cardiovascular disease, chronic organ failure and
malignancy [19] and it has been validated in our
local population [20]. Our data showed that every
point increase in CCI was associated with 24%
higher risk of in-hospital mortality.
Infection due to viridans group streptococci was
independently associated with a better outcome (OR
0.40). However, the association between S. aureus
(MSSA or MRSA) and clinical outcomes was not
reproduced in this study.
HCAIE has been increasingly common and was
associated with a worse outcome [14]. Our data
showed a higher in-hospital mortality among patients with HCAIE but the association became
insigniﬁcant after adjusting for comorbidities as
measured by CCI in the multivariable regression.
This shows that the difference in outcome may be
primarily driven by the increased number of underlying medical conditions and frailty in this group
of patients.
This study could not show any signiﬁcant association between systemic embolization and mortality,
probably due to the low number of embolic events
detected.
Last but not least, patients with possible IE were
shown to have a similar in-hospital and one-year
mortality as those with deﬁnite IE, consistent with
previous study [13]. Therefore, patients with
possible IE should also be closely monitored and
managed in the similar fashion as deﬁnite IE.
Study limitations
This study has several limitations and potential
biases. First, since it is a single-center and retrospective study, it is unable to prove causality and the
study ﬁndings cannot be generalized in the whole
population. Second, the CDARS was used to identify patients who were diagnosed with IE. This
method relied on physicians’ coding and was prone
to underreporting. In addition, the CDARS could
not retrieve the data of patients managed in the
private hospitals. These factors could have led to
underestimation of the true incidence. Third, the
data in the more recent years were not included, so
the latest trends in the community cannot be
completely reﬂected. Lastly, the practice in diagnosis and treatment of IE and related complications
could have changed signiﬁcantly during this long
study period.
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Conclusion
Our study conﬁrmed a relatively low and stable
incidence of IE in our population and detected an
increasing trend of health care-associated IE. S.
aureus has become the most common causative organism of IE, and its resistance to methicillin was
increasingly
observed.
In-hospital
mortality
remained high, and was independently associated
with higher Charlson Comorbidity Index, large
vegetation size and heart failure. Patients with IE
due to viridans group streptococci had a better
outcome.
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